Elanco Animal Health Incorporated (NYSE:ELAN) Given Average Recommendation of "Moderate Buy" by Brokerages

Key Points

• Elanco Animal Health has received an average rating of "Moderate Buy" from nine research firms, with three hold ratings, five buy ratings, and one strong buy rating.
• The company reported $0.26 earnings per share for the last quarter, exceeding analysts' expectations of $0.20, along with a revenue of $1.24 billion which is a 4.8% increase from the previous year.
• Hedge funds have significantly increased their stake in Elanco, with Allworth Financial LP increasing its holdings by 791.7% during the first quarter.

Shares of Elanco Animal Health Incorporated (NYSE:ELAN - Get Free Report) have earned a consensus recommendation of "Moderate Buy" from the nine research firms that are presently covering the company, Marketbeat.com reports. Three equities research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the company. The average 1 year target price among brokers that have issued ratings on the stock in the last year is $17.3333.

Several research firms have recently commented on ELAN. Leerink Partners raised shares of Elanco Animal Health from a "market perform" rating to an "outperform" rating and set a $18.00 price target on the stock in a research report on Thursday, July 17th. UBS Group lifted their price target on shares of Elanco Animal Health from $18.00 to $19.00 and gave the company a "buy" rating in a research report on Friday, August 8th. Stifel Nicolaus lifted their target price on shares of Elanco Animal Health from $16.00 to $17.00 and gave the company a "buy" rating in a report on Wednesday, July 2nd. Zacks Research downgraded shares of Elanco Animal Health from a "strong-buy" rating to a "hold" rating in a report on Wednesday, August 20th. Finally, Wall Street Zen upgraded shares of Elanco Animal Health from a "hold" rating to a "buy" rating in a research note on Saturday, July 5th.

Elanco Animal Health Price Performance

ELAN traded down $0.02 during trading on Friday, reaching $18.47. The company's stock had a trading volume of 345,216 shares, compared to its average volume of 5,517,768. The company has a quick ratio of 1.40, a current ratio of 2.60 and a debt-to-equity ratio of 0.61. The firm has a fifty day simple moving average of $15.35 and a two-hundred day simple moving average of $12.60. Elanco Animal Health has a 1 year low of $8.02 and a 1 year high of $18.87. The company has a market cap of $9.18 billion, a price-to-earnings ratio of 21.46, a PEG ratio of 3.32 and a beta of 1.66.

Elanco Animal Health (NYSE:ELAN - Get Free Report) last released its earnings results on Thursday, August 7th. The company reported $0.26 earnings per share for the quarter, topping analysts' consensus estimates of $0.20 by $0.06. The business had revenue of $1.24 billion for the quarter, compared to analyst estimates of $1.19 billion. Elanco Animal Health had a net margin of 9.68% and a return on equity of 7.04%. The business's revenue was up 4.8% on a year-over-year basis. During the same period last year, the company posted $0.30 EPS. Elanco Animal Health has set its Q3 2025 guidance at 0.120-0.160 EPS. FY 2025 guidance at 0.850-0.91 EPS. As a group, analysts anticipate that Elanco Animal Health will post 0.91 EPS for the current year.

Institutional Trading of Elanco Animal Health

Several large investors have recently modified their holdings of the business. Orion Porfolio Solutions LLC grew its position in shares of Elanco Animal Health by 35.5% in the second quarter. Orion Porfolio Solutions LLC now owns 71,768 shares of the company's stock valued at $1,025,000 after purchasing an additional 18,796 shares during the last quarter. Hudson Bay Capital Management LP grew its position in shares of Elanco Animal Health by 36.8% in the second quarter. Hudson Bay Capital Management LP now owns 273,620 shares of the company's stock valued at $3,907,000 after purchasing an additional 73,620 shares during the last quarter. Geneos Wealth Management Inc. grew its position in shares of Elanco Animal Health by 53.7% in the second quarter. Geneos Wealth Management Inc. now owns 5,954 shares of the company's stock valued at $85,000 after purchasing an additional 2,080 shares during the last quarter. CANADA LIFE ASSURANCE Co grew its position in shares of Elanco Animal Health by 9.3% in the second quarter. CANADA LIFE ASSURANCE Co now owns 120,815 shares of the company's stock valued at $1,729,000 after purchasing an additional 10,246 shares during the last quarter. Finally, Rakuten Securities Inc. lifted its stake in shares of Elanco Animal Health by 4.6% during the second quarter. Rakuten Securities Inc. now owns 39,000 shares of the company's stock valued at $557,000 after buying an additional 1,725 shares during the period. 97.48% of the stock is currently owned by institutional investors and hedge funds.

Elanco Animal Health Company Profile

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.